Here’s what you need to know:
1. One study used transient elastography and the AST to Platelet Ratio to evaluate the effects of Ocaliva on liver fibrosis. The study found Ocaliva-treated patients experienced improvements such as reduction in mean liver stiffness.
2. Another study focused on a subset of cirrhosis patients at the greatest risk of progression to liver-related adverse outcomes or death. The study found Ocaliva-treated patients experienced improvements in both cholestasis (alkaline phosphatase) and hepatic impairment (bilirubin).
3. A final study investigated the effects of Ocaliva in primary biliary cholangitis patients with mild and moderate renal impairment. The study found Ocaliva had no apparent effect on renal safety and patients experienced comparable results regardless of renal status.
More articles on gastroenterology and endoscopy:
Takeda Pharmaceutical, New York Academy of Sciences establish $200k research prize: 3 notes
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
AGA, NACCME develop 3 regional educational programs about IBD: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
